The American Journal of Managed Care13d
With Sub-Q Immunotherapy Coming, “Patient Preference Has to Be the Key”
An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.
Hosted on MSN2mon
Bristol Myers announces FDA approval of Opdivo Qvantig injection
Bristol Myers (BMY) Squibb announced that the U.S. FDA granted approval for Opdivo Qvantig injection for subcutaneous use, a combination product of nivolumab co-formulated with recombinant human ...
pharmaphorum3d
Opdivo's subcutaneous PD-1 inhibitor cleared in US
Opdivo Qvantig (nivolumab and hyaluronidase ... second drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza ...
Targeted Oncology4d
Dr. Galsky’s Perspectives on Subcutaneous ICI Dosing
An expert discusses how the availability of subcutaneous (SC) immune checkpoint inhibitors (ICI) for bladder cancer impacts ...
Zacks Investment Research on MSN13d
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC
Bristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo ...